HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/adlai-nortye-ltd" target="_blank" data-smartkarma-citation="entities:34049:1" rel="noopener">Adlai Nortye (ADN HK)</a> is a clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies for patients across various stages of tumors.</li>
<li> This article mainly analyzed the clinical-stage drug candidates in the pipeline, including AN2025, AN0025, AN1004, AN4005 and others.</li>
<li>Due to the concerns on early-stage pipeline, commercialization prospect, policy risks and the market's attitude towards license-in mode, we are conservative about the outlook of the Company at the current stage. </li>
</ul>



Adlai Nortye (ADN HK) is a clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies for patients across various stages of tumors.
 This article mainly analyzed the clinical-stage drug candidates in the pipeline, including AN2025, AN0025, AN1004, AN4005 and others.
Due to the concerns on early-stage pipeline, commercialization prospect, policy risks and the market's attitude towards license-in mode, we are conservative about the outlook of the Company at the current stage. 


Pre-IPO Adlai Nortye - Insights on Pipeline and Concerns

<p><a href="https://www.smartkarma.com/entities/lianbio" target="_blank" data-smartkarma-citation="entities:34478:1" rel="noopener">LianBio (LIAN US)</a> is about to officially list on NASDAQ. Based on license-in mode, LianBio has assembled a pipeline of nine assets across five therapeutic areas in less than three years, covering cardiovascular, oncology, ophthalmology, inflammatory disease and respiratory indications. In fact, as of mid-August this year, LianBio ranked first among domestic pharmaceutical companies in terms of the number of license-in projects with five new drugs. The late-stage development pipeline is led by mavacamten, infigratinib, TP-03, NBTXR3 and LYR-210, which would be commercialized in Greater China and other Asian markets. This insight mainly analyzed these late-stage candidates as well as the concerns of the Company.</p>

LianBio (LIAN US) is about to officially list on NASDAQ. Based on license-in mode, LianBio has assembled a pipeline of nine assets across five therapeutic areas in less than three years, covering cardiovascular, oncology, ophthalmology, inflammatory disease and respiratory indications. In fact, as of mid-August this year, LianBio ranked first among domestic pharmaceutical companies in terms of the number of license-in projects with five new drugs. The late-stage development pipeline is led by mavacamten, infigratinib, TP-03, NBTXR3 and LYR-210, which would be commercialized in Greater China and other Asian markets. This insight mainly analyzed these late-stage candidates as well as the concerns of the Company.

Pre-IPO LianBio (LIAN.US) - The Strength and the Concerns

United States

LianBio operates as a biological technology company. The Company develops therapies to treat cardiovascular, oncology, respiratory, ophthalmology and inflammatory disease. LianBio serves customers patients in Asia.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

LianBio (LIAN US)

Pre-IPO Adlai Nortye - Insights on Pipeline and Concerns

This article mainly analyzed Adlai Nortye in terms of its important clinical-stage drug candidates, the competition pattern, commercialization...

Xinyao (Criss) Wang

Pre-IPO LianBio (LIAN.US) - The Strength and the Concerns

The insight mainly analyzed LianBio in terms of late-stage candidates (mavacamten, infigratinib, TP-03, NBTXR3, LYR-210), and concerns on domestic...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)